Beta Bionics Q3 adjusted EBITDA misses estimates
BBNX•Beta Bionics reported Q3 net sales of $35.51 million, up 30% and above estimates, while adjusted EBITDA was a loss of $18.91 million, missing estimates. The company raised its 2026 revenue guidance to $124 million-$126 million.
1. Q3 results
Beta Bionics reported Q3 net sales of $35.51 million, compared with analyst estimates of $34.72 million. Adjusted EBITDA was a loss of $18.91 million, versus an estimated loss of $18.46 million, and the operating loss of $26.61 million was a slight miss.
2. Guidance and sales drivers
The company raised its 2026 revenue guidance to $124 million-$126 million from $121 million-$126 million. It expects up to $8.5 million in Q4 2026 revenue deferral as customers await the Mint launch, and expects Mint to recapture any lost Q4 revenue during 2027. Pharmacy Benefit Plan channel net sales rose 118% year on year, while gross margin increased 179 basis points to 57.3%.
